Metastatic Melanoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Metastatic Melanoma – Pipeline Review, H2 2016’, provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma

The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects

The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB Science SA

AbbVie Inc

Adaptimmune Therapeutics Plc

Affichem SA

Agalimmune Ltd

AGV Discovery, SAS

Altor BioScience Corporation

Amgen Inc.

Angimmune LLC

Apexigen, Inc.

Arisaph Pharmaceuticals, Inc.

Array BioPharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Basilea Pharmaceutica Ltd.

Bellicum Pharmaceuticals, Inc.

BerGenBio AS

Bioncotech Therapeutics SL

Bionomics Limited

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Calithera Biosciences, Inc.

Cellceutix Corporation

Celldex Therapeutics, Inc.

Cortice Biosciences, Inc.

Delcath Systems, Inc.

Digna Biotech, S.L.

Dynavax Technologies Corporation

Eisai Co., Ltd.

Eli Lilly and Company

Ensol Biosciences Inc.

F. Hoffmann-La Roche Ltd.

Galapagos NV

Galectin Therapeutics, Inc.

GlaxoSmithKline Plc

Idera Pharmaceuticals, Inc.

Ignyta, Inc.

Immune Design Corp.

Immunocore Limited

ImmuRx, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

IO Biotech ApS

Lentigen Technology, Inc.

Life Science Pharmaceuticals, Incorporated

Lipotek Pty Ltd.

MacroGenics, Inc.

MedImmune, LLC

Medivation, Inc.

MELEMA Pharma GmbH

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Modulate Therapeutics, Inc.

Moleculin Biotech Inc

Morphotek, Inc.

NewLink Genetics Corporation

Novartis AG

Omeros Corporation

Oncolytics Biotech Inc.

OncoSec Medical Incorporated

Onxeo SA

Pfizer Inc.

Pharmis Biofarmaceutica, Lda.

Philogen S.p.A.

PinCell srl

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Prima BioMed Ltd.

Provectus Biopharmaceuticals, Inc.

Provenance Biopharmaceuticals Corp.

Reata Pharmaceuticals, Inc.

Recepta Biopharma S.A.

RXi Pharmaceuticals Corporation

Scancell Holdings Plc

Sillajen Biotherapeutics

SolaranRx, Inc.

Syndax Pharmaceuticals Inc

Takara Bio Inc.

TC BioPharm Limited

Tikcro Technologies, Ltd.

Ultimovacs AS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Metastatic Melanoma Overview 8

Therapeutics Development 9

Metastatic Melanoma - Therapeutics under Development by Companies 11

Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes 17

Metastatic Melanoma - Pipeline Products Glance 19

Metastatic Melanoma - Products under Development by Companies 22

Metastatic Melanoma - Products under Investigation by Universities/Institutes 30

Metastatic Melanoma - Companies Involved in Therapeutics Development 31

Metastatic Melanoma - Therapeutics Assessment 113

Drug Profiles 137

Metastatic Melanoma - Dormant Projects 601

Metastatic Melanoma - Discontinued Products 615

Metastatic Melanoma - Product Development Milestones 617

Appendix 631

List of Tables

List of Tables

Number of Products under Development for Metastatic Melanoma, H2 2016 25

Number of Products under Development for Metastatic Melanoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Development by Companies, H2 2016 (Contd..1) 28

Number of Products under Development by Companies, H2 2016 (Contd..2) 29

Number of Products under Development by Companies, H2 2016 (Contd..3) 30

Number of Products under Development by Companies, H2 2016 (Contd..4) 31

Number of Products under Development by Companies, H2 2016 (Contd..5) 32

Number of Products under Investigation by Universities/Institutes, H2 2016 34

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Development, H2 2016 37

Products under Development by Companies, H2 2016 38

Products under Development by Companies, H2 2016 (Contd..1) 39

Products under Development by Companies, H2 2016 (Contd..2) 40

Products under Development by Companies, H2 2016 (Contd..3) 41

Products under Development by Companies, H2 2016 (Contd..4) 42

Products under Development by Companies, H2 2016 (Contd..5) 43

Products under Development by Companies, H2 2016 (Contd..6) 44

Products under Development by Companies, H2 2016 (Contd..7) 45

Products under Investigation by Universities/Institutes, H2 2016 46

Metastatic Melanoma – Pipeline by AB Science SA, H2 2016 47

Metastatic Melanoma – Pipeline by AbbVie Inc, H2 2016 48

Metastatic Melanoma – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 49

Metastatic Melanoma – Pipeline by Affichem SA, H2 2016 50

Metastatic Melanoma – Pipeline by Agalimmune Ltd, H2 2016 51

Metastatic Melanoma – Pipeline by AGV Discovery, SAS, H2 2016 52

Metastatic Melanoma – Pipeline by Altor BioScience Corporation, H2 2016 53

Metastatic Melanoma – Pipeline by Amgen Inc., H2 2016 54

Metastatic Melanoma – Pipeline by Angimmune LLC, H2 2016 55

Metastatic Melanoma – Pipeline by Apexigen, Inc., H2 2016 56

Metastatic Melanoma – Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 57

Metastatic Melanoma – Pipeline by Array BioPharma Inc., H2 2016 58

Metastatic Melanoma – Pipeline by Astex Pharmaceuticals, Inc., H2 2016 59

Metastatic Melanoma – Pipeline by AstraZeneca Plc, H2 2016 60

Metastatic Melanoma – Pipeline by Basilea Pharmaceutica Ltd., H2 2016 61

Metastatic Melanoma – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 62

Metastatic Melanoma – Pipeline by BerGenBio AS, H2 2016 63

Metastatic Melanoma – Pipeline by Bioncotech Therapeutics SL, H2 2016 64

Metastatic Melanoma – Pipeline by Bionomics Limited, H2 2016 65

Metastatic Melanoma – Pipeline by Boehringer Ingelheim GmbH, H2 2016 66

Metastatic Melanoma – Pipeline by Bristol-Myers Squibb Company, H2 2016 67

Metastatic Melanoma – Pipeline by Calithera Biosciences, Inc., H2 2016 68

Metastatic Melanoma – Pipeline by Cellceutix Corporation, H2 2016 69

Metastatic Melanoma – Pipeline by Celldex Therapeutics, Inc., H2 2016 70

Metastatic Melanoma – Pipeline by Cortice Biosciences, Inc., H2 2016 71

Metastatic Melanoma – Pipeline by Delcath Systems, Inc., H2 2016 72

Metastatic Melanoma – Pipeline by Digna Biotech, S.L., H2 2016 73

Metastatic Melanoma – Pipeline by Dynavax Technologies Corporation, H2 2016 74

Metastatic Melanoma – Pipeline by Eisai Co., Ltd., H2 2016 75

Metastatic Melanoma – Pipeline by Eli Lilly and Company, H2 2016 76

Metastatic Melanoma – Pipeline by Ensol Biosciences Inc., H2 2016 77

Metastatic Melanoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 78

Metastatic Melanoma – Pipeline by Galapagos NV, H2 2016 79

Metastatic Melanoma – Pipeline by Galectin Therapeutics, Inc., H2 2016 80

Metastatic Melanoma – Pipeline by GlaxoSmithKline Plc, H2 2016 81

Metastatic Melanoma – Pipeline by Idera Pharmaceuticals, Inc., H2 2016 82

Metastatic Melanoma – Pipeline by Ignyta, Inc., H2 2016 83

Metastatic Melanoma – Pipeline by Immune Design Corp., H2 2016 84

Metastatic Melanoma – Pipeline by Immunocore Limited, H2 2016 85

Metastatic Melanoma – Pipeline by ImmuRx, Inc., H2 2016 86

Metastatic Melanoma – Pipeline by Incyte Corporation, H2 2016 87

Metastatic Melanoma – Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 88

Metastatic Melanoma – Pipeline by IO Biotech ApS, H2 2016 89

Metastatic Melanoma – Pipeline by Lentigen Technology, Inc., H2 2016 90

Metastatic Melanoma – Pipeline by Life Science Pharmaceuticals, Incorporated, H2 2016 91

Metastatic Melanoma – Pipeline by Lipotek Pty Ltd., H2 2016 92

Metastatic Melanoma – Pipeline by MacroGenics, Inc., H2 2016 93

Metastatic Melanoma – Pipeline by MedImmune, LLC, H2 2016 94

Metastatic Melanoma – Pipeline by Medivation, Inc., H2 2016 95

Metastatic Melanoma – Pipeline by MELEMA Pharma GmbH , H2 2016 96

Metastatic Melanoma – Pipeline by Merck & Co., Inc., H2 2016 97

Metastatic Melanoma – Pipeline by Merck KGaA, H2 2016 98

Metastatic Melanoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 99

Metastatic Melanoma – Pipeline by Modulate Therapeutics, Inc., H2 2016 100

Metastatic Melanoma – Pipeline by Moleculin Biotech Inc, H2 2016 101

Metastatic Melanoma – Pipeline by Morphotek, Inc., H2 2016 102

Metastatic Melanoma – Pipeline by NewLink Genetics Corporation, H2 2016 103

Metastatic Melanoma – Pipeline by Novartis AG, H2 2016 104

Metastatic Melanoma – Pipeline by Omeros Corporation, H2 2016 105

Metastatic Melanoma – Pipeline by Oncolytics Biotech Inc., H2 2016 106

Metastatic Melanoma – Pipeline by OncoSec Medical Incorporated, H2 2016 107

Metastatic Melanoma – Pipeline by Onxeo SA, H2 2016 108

Metastatic Melanoma – Pipeline by Pfizer Inc., H2 2016 109

Metastatic Melanoma – Pipeline by Pharmis Biofarmaceutica, Lda., H2 2016 110

Metastatic Melanoma – Pipeline by Philogen S.p.A., H2 2016 111

Metastatic Melanoma – Pipeline by PinCell srl, H2 2016 112

Metastatic Melanoma – Pipeline by Plexxikon Inc., H2 2016 113

Metastatic Melanoma – Pipeline by Polaris Pharmaceuticals, Inc., H2 2016 114

Metastatic Melanoma – Pipeline by Prima BioMed Ltd., H2 2016 115

Metastatic Melanoma – Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 116

Metastatic Melanoma – Pipeline by Provenance Biopharmaceuticals Corp., H2 2016 117

Metastatic Melanoma – Pipeline by Reata Pharmaceuticals, Inc., H2 2016 118

Metastatic Melanoma – Pipeline by Recepta Biopharma S.A., H2 2016 119

Metastatic Melanoma – Pipeline by RXi Pharmaceuticals Corporation, H2 2016 120

Metastatic Melanoma – Pipeline by Scancell Holdings Plc, H2 2016 121

Metastatic Melanoma – Pipeline by Sillajen Biotherapeutics, H2 2016 122

Metastatic Melanoma – Pipeline by SolaranRx, Inc., H2 2016 123

Metastatic Melanoma – Pipeline by Syndax Pharmaceuticals Inc, H2 2016 124

Metastatic Melanoma – Pipeline by Takara Bio Inc., H2 2016 125

Metastatic Melanoma – Pipeline by TC BioPharm Limited, H2 2016 126

Metastatic Melanoma – Pipeline by Tikcro Technologies, Ltd., H2 2016 127

Metastatic Melanoma – Pipeline by Ultimovacs AS, H2 2016 128

Assessment by Monotherapy Products, H2 2016 129

Assessment by Combination Products, H2 2016 130

Number of Products by Stage and Target, H2 2016 132

Number of Products by Stage and Mechanism of Action, H2 2016 141

Number of Products by Stage and Route of Administration, H2 2016 150

Number of Products by Stage and Molecule Type, H2 2016 152

Metastatic Melanoma – Dormant Projects, H2 2016 617

Metastatic Melanoma – Dormant Projects (Contd..1), H2 2016 618

Metastatic Melanoma – Dormant Projects (Contd..2), H2 2016 619

Metastatic Melanoma – Dormant Projects (Contd..3), H2 2016 620

Metastatic Melanoma – Dormant Projects (Contd..4), H2 2016 621

Metastatic Melanoma – Dormant Projects (Contd..5), H2 2016 622

Metastatic Melanoma – Dormant Projects (Contd..6), H2 2016 623

Metastatic Melanoma – Dormant Projects (Contd..7), H2 2016 624

Metastatic Melanoma – Dormant Projects (Contd..8), H2 2016 625

Metastatic Melanoma – Dormant Projects (Contd..9), H2 2016 626

Metastatic Melanoma – Dormant Projects (Contd..10), H2 2016 627

Metastatic Melanoma – Dormant Projects (Contd..11), H2 2016 628

Metastatic Melanoma – Dormant Projects (Contd..12), H2 2016 629

Metastatic Melanoma – Dormant Projects (Contd..13), H2 2016 630

Metastatic Melanoma – Discontinued Products, H2 2016 631

Metastatic Melanoma – Discontinued Products (Contd..1), H2 2016 632

List of Figures

List of Figures

Number of Products under Development for Metastatic Melanoma, H2 2016 25

Number of Products under Development for Metastatic Melanoma – Comparative Analysis, H2 2016 26

Number of Products under Development by Companies, H2 2016 27

Number of Products under Investigation by Universities/Institutes, H2 2016 33

Comparative Analysis by Late Stage Development, H2 2016 35

Comparative Analysis by Clinical Stage Development, H2 2016 36

Comparative Analysis by Early Stage Products, H2 2016 37

Assessment by Monotherapy Products, H2 2016 129

Assessment by Combination Products, H2 2016 130

Number of Products by Top 10 Targets, H2 2016 131

Number of Products by Stage and Top 10 Targets, H2 2016 131

Number of Products by Top 10 Mechanism of Actions, H2 2016 140

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 140

Number of Products by Top 10 Routes of Administration, H2 2016 149

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 149

Number of Products by Top 10 Molecule Types, H2 2016 151

Number of Products by Stage and Top 10 Molecule Types, H2 2016 151

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports